Enfusion Inc Stock Price, News & Analysis

Enfusion, Inc. (NYSE: ENFN) released its fourth quarter and full year 2022 financial results through its Shareholder Letter. The company specializes in cloud-native SaaS solutions for investment managers, serving over 800 clients globally. Enfusion’s platform integrates front, middle, and back-office teams, enhancing data-driven decision-making and operational efficiency. A conference call to discuss the Q4 earnings took place on March 7, 2022, at 8:30 am ET, allowing analysts and investors to gain insights into the company's performance and strategy moving forward. For more details, the shareholder letter is accessible on Enfusion's Investor Relations website.

Enfusion, Inc. (NYSE: ENFN) will release its fourth quarter and full year 2022 financial results on March 7, 2023, before the U.S. markets open. A conference call will take place at 5:30 AM (PT) / 8:30 AM (ET) the same morning to discuss the results. Investors can access the call by dialing (833) 470-1428 for domestic or (929) 526-1599 for international participants, using conference ID 603560. A live webcast will be available on Enfusion's Investor Relations page, with a replay archived afterward. Enfusion provides cloud-native SaaS solutions, partnering with over 800 investment managers globally.

Enfusion, Inc. has appointed Michael Spellacy as Board Chair effective January 9, 2023. His extensive experience in investment management technology and strategic leadership is expected to benefit the company's growth. Interim Chair Kathleen DeRose expressed confidence in Spellacy's ability to advance Enfusion's strategy amidst a challenging economic landscape. Enfusion provides cloud-native software solutions for investment managers, with over 800 clients globally. This leadership change aims to enhance client success and further innovation in their services.

Enfusion, Inc. (NYSE: ENFN) has appointed Oleg Movchan as Chief Executive Officer, effective December 22, 2022, after serving as interim CEO since August 21, 2022. Kathleen DeRose, Interim Chair of the Board, praised Movchan's impact and leadership capabilities. With over ten years as an investor and board member, Movchan brings extensive experience in investment management and holds multiple advanced degrees. He aims to strengthen Enfusion's position in the investment management software market while enhancing client and shareholder value.

Enfusion, Inc. has appointed Brad Herring as its new Chief Financial Officer. Herring is a seasoned executive with extensive experience in the FinTech and SaaS sectors, previously serving as CFO for Shift4 Payments, where he led a $450 million IPO. Interim CEO Oleg Movchan expressed enthusiasm about Herring's leadership, anticipating his contributions to Enfusion's growth. The company provides cloud-native SaaS solutions aimed at improving investment management processes across front, middle, and back-office teams.

Enfusion (NYSE: ENFN) has appointed Deirdre Somers to its Board of Directors, effective January 1, 2023. With over 30 years of experience in asset management, including her role as a former CEO of a securities exchange, Somers will also serve on the Audit and Nominating and Corporate Governance Committees. Interim Chair Kathleen DeRose highlighted her global perspective as a significant asset in expanding Enfusion's footprint in the investment management industry.

FTV Capital has appointed six financial services executives to its Strategic Advisory Board, enhancing its Global Partner Network. New members include industry leaders from Liberty Mutual, Silicon Valley Bank, and Citi, among others. This Board will convene biannually to discuss market trends and facilitate connections within FTV’s portfolio. Established in 1999, the Board provides vital market intelligence and strategic introductions for portfolio companies, focusing on themes like supply chain management and healthcare cost containment. FTV has raised $6.2 billion and invested in over 130 companies.

Enfusion, Inc. (NYSE: ENFN) announced the resignation of Chief Financial Officer Stephen Dorton, effective January 6, 2023. His departure is attributed to pursuing another career opportunity and not due to any disagreements with the company. Interim CEO Oleg Movchan expressed gratitude for Dorton's contributions, highlighting the company's growth during his tenure. Enfusion maintains strong demand for its cloud-native solutions and reiterates its guidance for Q4 and full year 2022. The company is actively searching for a new CFO as part of its succession plan.